Dual Blockade of Inhibitory Immunoreceptors TIGIT and PD-1 Produces Optimal Synergistic Anti-Tumor Effects

Authors

  • Paige Kramer

DOI:

https://doi.org/10.17161/mjusc.v1i1.18573

Keywords:

Immunology, TIGIT, PD-1, checkpoint inhibitors, tumor, cancer

Abstract

Recent investigation into immunoregulatory roles of both TIGIT and PD-1 T cell receptors reveals that their suppressive effects converge with the inhibition of another T cell receptor, CD226. Co-blockade of these receptors reduced tumor volume in vivo and shows potential as a promising new cancer immunotherapy.

Cover of issue 1 of the Midwestern Journal of Undergraduate Sciences showing an illustration of checkpoint inhibitors

Downloads

Published

2022-10-03

Issue

Vol. 1 No. 1 (2022)

Section

Reviews

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license. 

How to Cite

Kramer, P. (2022). Dual Blockade of Inhibitory Immunoreceptors TIGIT and PD-1 Produces Optimal Synergistic Anti-Tumor Effects. Midwestern Journal of Undergraduate Sciences, 1(1), 3-4. https://doi.org/10.17161/mjusc.v1i1.18573